AU2003903274A0 - Method of assessing cancer risk - Google Patents

Method of assessing cancer risk

Info

Publication number
AU2003903274A0
AU2003903274A0 AU2003903274A AU2003903274A AU2003903274A0 AU 2003903274 A0 AU2003903274 A0 AU 2003903274A0 AU 2003903274 A AU2003903274 A AU 2003903274A AU 2003903274 A AU2003903274 A AU 2003903274A AU 2003903274 A0 AU2003903274 A0 AU 2003903274A0
Authority
AU
Australia
Prior art keywords
cancer risk
assessing cancer
assessing
risk
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003903274A
Inventor
Kanaga Sabapathy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SABAPATHY K
Original Assignee
SABAPATHY K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SABAPATHY K filed Critical SABAPATHY K
Priority to AU2003903274A priority Critical patent/AU2003903274A0/en
Publication of AU2003903274A0 publication Critical patent/AU2003903274A0/en
Priority to PCT/SG2004/000189 priority patent/WO2005001127A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003903274A 2003-06-27 2003-06-27 Method of assessing cancer risk Abandoned AU2003903274A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003903274A AU2003903274A0 (en) 2003-06-27 2003-06-27 Method of assessing cancer risk
PCT/SG2004/000189 WO2005001127A1 (en) 2003-06-27 2004-06-25 P53 as an indicator of cancer risk in different ethnic groups

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003903274A AU2003903274A0 (en) 2003-06-27 2003-06-27 Method of assessing cancer risk

Publications (1)

Publication Number Publication Date
AU2003903274A0 true AU2003903274A0 (en) 2003-07-10

Family

ID=31954311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003903274A Abandoned AU2003903274A0 (en) 2003-06-27 2003-06-27 Method of assessing cancer risk

Country Status (2)

Country Link
AU (1) AU2003903274A0 (en)
WO (1) WO2005001127A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231304A1 (en) * 2006-01-30 2007-10-04 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
EP1847595B1 (en) 2006-04-20 2010-01-06 Northern Sydney and Central Coast Area Health Service Methods of assessing embryo viability
WO2013035114A1 (en) * 2011-09-08 2013-03-14 Decode Genetics Ehf Tp53 genetic variants predictive of cancer
CN112725422A (en) * 2021-02-26 2021-04-30 山东康华生物医疗科技股份有限公司 Primer, probe and kit for HRAS G13R mutation detection

Also Published As

Publication number Publication date
WO2005001127A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AU2003226301A1 (en) Method of treating cancer
AU2003258855A1 (en) Method for the reduction of acrylamide formation
GB0325192D0 (en) Method of use
AU2003256847A1 (en) Method of treating cancer
AU2005316238B2 (en) Cancer treatment method
SG112017A1 (en) Method of determining shape data
AU2003277596A1 (en) Method of deuterization
AU2003901361A0 (en) Method of enhancing fluorescence
AU2003256995A1 (en) Method for identifying cancer risk
AU2003202205A1 (en) Methods for identifying cancer risk
AU2003280558A1 (en) Method for treatment of cancer
AU2003902613A0 (en) Self-surveying method
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003218208A1 (en) Methods for diagnosis and prognosis of cancer
AU2003900325A0 (en) Identifying apparatus
AU2003901196A0 (en) Analysis method
AU2003903274A0 (en) Method of assessing cancer risk
AU2003294272A1 (en) Methods for diagnosing the presence or stage of cancer
AU2003263728A1 (en) Method for diagnosis of cancer
AU2003272972A1 (en) Method of treatment for cancer
AU2003220903A1 (en) Method of judging risk of peiodontal disease
AU2003290512A1 (en) Method of weldbonding
AU2003299623A1 (en) Method of making mercaptoalkylalkyldialkoxysilanes
AU2003901267A0 (en) Assessment method
AU2003223317A1 (en) Determining cancer aggressiveness